



INFORMAZIONI PERSONALI

Saverio Bettuzzi



 Dipartimento di Medicina e Chirurgia
 Unità di Biochimica, Oncologia Molecolare e Traslazionale
 Università degli Studi di Parma
 Via Volturmo, 39- 43126 PARMA – ITALY

 0521-033803

 saverio.bettuzzi@unipr.it

Web sites:

<http://www.unipr.it/ugov/person/15051>

<http://scholar.google.it/citations?hl=it&user=iDYHZ-gAAAAJ>

Sesso M |

Data di nascita 19/09/1958 |

Nazionalità italiana

Candidatura a Rettore per il sessennio 2017/2018-2022/2023

POSIZIONE RICOPERTA

Professore Ordinario di Biochimica, SSD BIO/10, Università di Parma

TITOLO DI STUDIO

Laurea in Biologia

Specializzazione in Biochimica Marina

Dottorato di Ricerca in Biochimica

ESPERIENZA PROFESSIONALE

- Consigliere di Amministrazione dell'Ateneo di Parma da gennaio 2017
- 2014-2016: Membro della Commissione ASN per le Abilitazioni Nazionali del settore BIO/10, tornata 2013.
- 2005-presente: Professore Ordinario di Biochimica, Facoltà di Medicina, Università di Parma
- 2001-2005: Professore Associato di Biochimica, Facoltà di Medicina, Università di Parma
- 2000-2001: Direttore di Ricerca (Dirigente) Aczon SrL Bologna
- 1996-2000: Borsa post-dottorato in Biochimica, Università di Modena
- 1984-2000: Professore di Ruolo, Scuola Secondaria Superiore, Provveditorato agli Studi di Modena
- 1987-89: Research Associate, Ben May Institute for Cancer Research, University of Chicago, USA.
- 1984-1986: Post-Doctoral Fellowship in Biochimica, Università di Modena

Valutazione ANVUR 2004-2010 Per l'Università di Parma, tutti e tre i prodotti scientifici selezionati sono stati valutati 1 (eccellente)

Coordinamento progetti di ricerca nazionali ed internazionali

AIRC 2002 e 2003
PRIN2004-2006, Coordinatore nazionale
CIRC 2005, Coordinatore
Azioni Integrate Italia-Spagna 2005-2006, IT2510, Coordinatore nazionale
ABO Project 2005-2006, Principal Investigator
AICR (UK) 2007-2009, GRANT No. 06-711, Principal Investigator
CARIPARMA 2010, progetto scientifico, Coordinatore unità locale
PRIN2008-2010, Coordinatore unità locale
COMT 2010-14
CARIPARMA 2011
CARIPARMA 2016
Fondi locali FIL, sempre finanziato dal 2002 al 2015

Valutatore per organismi nazionali e internazionali

Ha prestato servizio come Commissario, Segretario o Presidente in numerosi concorsi di valutazione comparativa per l'assunzione in ruolo di Ricercatori Universitari (RU), Professori Associati (PA) e Professori Ordinari (PO), inclusi procedimenti di valutazione per chiamata diretta.

Valutatore nazionale:
progetti FIRB, SIR, PRINN, Provincia di Bolzano, Regione Calabria, MIUR

Valutatore internazionale:
FP-6 (EU)
BBSRC (UK)
Medical Research Council, Molecular Cellular Medicine (UK)
Ben Gurion University (Israel)
French National Cancer Institute (Fr)
Georgia National Science Foundation (Georgia)
Spanish Ministry of Health (Spain)
Swiss National Science Foundation (SNSF)
The Prostate Cancer Charity (UK)

Reviewer di oltre 60 riviste internazionali, tra cui Science e Nature

ISTRUZIONE E FORMAZIONE

- 1986-1990 Dottorato in Biochimica, Università di Bologna, Diploma rilasciato con i Complimenti della Commissione Giudicatrice
- 1981-1983 Scuola di Specializzazione in Biochimica Marina, Università di Bologna, 70/70 con Lode
- 1978-1981 Laurea in Biologia, Università di Bologna, 110/110, con Lode

COMPETENZE PERSONALI

Lingua madre Italiano

Altre lingue	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
Inglese	Fluent, C2	Fluent, C2	Fluent, C2	Fluent, C2	Fluent, C2

Competenze comunicative

- Ottime competenze comunicative acquisite durante l'esperienza di Docente a livello Secondario e Universitario

Competenze organizzative e gestionali

- Leadership di ricerca, attualmente responsabile di un team di 5 persone presso l'Università di Parma;
- gestione di numerose collaborazioni internazionali;
- organizzazione di congressi internazionali come membro del Board scientifico (CLU/ApoJ 2011; XXV Congress of Polish Physiological Society, 2011; CLU/ApoJ 2014; XXVI Congress of Polish Physiological Society 2014; ESUR2016)
- Vice Presidente e membro del Consiglio Direttivo di COMT, Centro interdipartimentale di Oncologia Molecolare e Translazionale, Università di Parma (<http://www.unipr.it/ateneo/organ-e-strutture/centri-e-altre-strutture/centri-universitari/comt-centro>)
- Membro del Direttivo INBB, Istituto Nazionale Biostrutture e Biosistemi, Roma, per il quale ogni anno organizza il congresso nazionale (www.inbb.it)
- Membro del Comitato Ordinatore della Scuola di Specializzazione in Patologia e Biochimica Clinica dell'Università di Parma

Competenze professionali

- Ottima padronanza delle competenze necessarie per la didattica e la ricerca scientifica
- Membro del Collegio dei Docenti del Dottorato di Medicina Molecolare
- Coordinatore del corso di Biochimica Dinamica e Sistematica Umana nel CdS a Ciclo Unico in Medicina e Chirurgia
- Coordinatore del corso di Biochimica e Metabolismo nello Sport nel CdS Magistrale in Scienze e Tecniche delle Attività Motorie Preventive e Adattate
- Coordinatore del corso di Fisiologia Umana e Biochimica Clinica nel CdS di Tecnico di Laboratorio Biomedico
- Docente del corso di Biochimica e Biologia Molecolare nel CdS a Ciclo Unico in Medicina e Chirurgia
- Docente del corso di Stili di Vita e Benessere nel CdS a Ciclo Unico in Medicina e Chirurgia

Competenza digitale

AUTOVALUTAZIONE				
Elaborazione delle informazioni	Comunicazione	Creazione di Contenuti	Sicurezza	Risoluzione di problemi
Intermedio	Intermedio	Intermedio	Intermedio	Intermedio

- ottima padronanza degli strumenti della suite per ufficio (elaboratore di testi, foglio elettronico)
- ottima padronanza di software di presentazione
- buona padronanza dei programmi per l'elaborazione digitale delle immagini e protezione dati

Interessi scientifici (key words)

Clusterin (CLU), Prostate Cancer (PCa), Green Tea, Catechins, Polyphenols, EGCG, Chemoprevention, Biochemistry and Molecular Biology of Cancer, Physiology and Pathology of the Prostate, Cell Growth Control, Prostate Metabolism, Androgen Action on Prostate Cells, Polyamines, Gene expression, Epigenetic Regulation of Gene Expression.

Patente di guida

A e B

ULTERIORI INFORMAZIONI

Biography (in English)

Dr. Saverio Bettuzzi received a PhD in Biology in 1981, the University Diploma in Marine Biochemistry in 1983 and the Doctorate in Biochemistry in 1990, all from the University of Bologna, Italy. He was a Postdoctoral Fellow in Biochemistry (1984–1986) at the University of Modena, Italy, and a Research Associate at the Ben May Institute for Cancer Research at the University of Chicago, USA (1987–1989). After returning to Italy, he

became a Postdoctoral Fellow in Biochemistry at the University of Modena (1996–2000), Associate Professor of Biochemistry (2001-2005), and Full Professor of Biochemistry (2005-present) at the University of Parma, where he is Vice-Dean of the School of Medicine and Vice-Director of COMT. He is Board member of INBB, Rome, and ESUR (European Section of Urological Research). He heads a research group with multiple international collaborations, and hosted international meetings. He cloned and identified Clusterin (CLU) as the major over-expressed gene during castration-induced involution of rat prostate in 1989. His research has focused on understanding the regulation of expression and the biological role of CLU as a tumor suppressor for Prostate, Colon, Ovarian, Lung Cancers and Neuroblastoma. He did original research on the activity of Green Tea (GTE) and showed that progression of Prostate Cancer can be blocked with GTE in mouse models and humans. He also validated a qPCR method for molecular diagnosis and prognosis of Prostate Cancer in humans. His group recently discovered and characterized a novel P2 promoter of CLU in humans, which is regulated epigenetically.

Pubblicazioni Internazionali
(ISI, peer-reviewed)

1. Green Tea Catechins for Prostate Cancer Prevention: Present Achievements and Future Challenges.
Naponelli V, Ramazzina I, Lenzi C, Bettuzzi S, Rizzi F.
Antioxidants (Basel). 2017 Apr 5;6(2). pii: E26. doi: 10.3390/antiox6020026. Review.
- 1a. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Klionsky DJ, et al. *Autophagy*. 2016 Jan 2;12(1):1-222.
2. EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism.
Modernelli A, Naponelli V, Giovanna Troglio M, Bonacini M, Ramazzina I, Bettuzzi S, Rizzi F.
Sci Rep. 2015 Oct 16;5:15270. doi: 10.1038/srep15270.
3. Control of autophagy in cancer.
Orzechowski A, Bettuzzi S, Pawlikowska P, Pająk B.
Biomed Res Int. 2015;2015:698740. doi: 10.1155/2015/698740.
4. Roles of autophagy induced by natural compounds in prostate cancer.
Naponelli V, Modernelli A, Bettuzzi S, Rizzi F.
Biomed Res Int. 2015;2015:121826. doi: 10.1155/2015/121826.
5. Distinct promoters, subjected to epigenetic regulation, drive the expression of two clusterin mRNAs in prostate cancer cells.
Bonacini M, Coletta M, Ramazzina I, Naponelli V, Modernelli A, Davalli P, Bettuzzi S, Rizzi F. *Biochim Biophys Acta*. 2015 Jan;1849(1):44-54. doi: 10.1016/j.bbagr.2014.11.003.
6. Polyphenon E(R), a standardized green tea extract, induces endoplasmic reticulum stress, leading to death of immortalized PNT1a cells by anoikis and tumorigenic PC3 by necroptosis.
Rizzi F, Naponelli V, Silva A, Modernelli A, Ramazzina I, Bonacini M, Tardito S, Gatti R, Uggeri J, Bettuzzi S.
Carcinogenesis. 2014 Apr;35(4):828-39. doi: 10.1093/carcin/bgt481.
7. Prognostic role of clusterin in resected adenocarcinomas of the lung.
Panico F, Casali C, Rossi G, Rizzi F, Morandi U, Bettuzzi S, Davalli P, Corbetta L, Storelli ES, Corti A, Fabbri LM, Astancolle S, Luppi F.
Lung Cancer. 2013 Mar;79(3):294-9. doi: 10.1016/j.lungcan.2012.11.024.
8. Anticancer activity of green tea polyphenols in prostate gland.

- Davalli P, Rizzi F, Caporali A, Pellacani D, Davoli S, Bettuzzi S, Brausi M, D'Arca D. *Oxid Med Cell Longev*. 2012;2012:984219. doi: 10.1155/2012/984219. 8.
9. Health Benefits of Tea.
Serafini M, Del Rio D, Yao DN, Bettuzzi S, Peluso I.
In: Benzie IFF, Wachtel-Galor S, editors. *Herbal Medicine: Biomolecular and Clinical Aspects*. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 12.
10. Chronic administration of green tea extract to TRAMP mice induces the collapse of Golgi apparatus in prostate secretory cells and results in alterations of protein post-translational processing.
Davalli P, Rizzi F, Caldara GF, Davoli S, Corti A, Silva A, Astancolle S, Vitale M, Bettuzzi S, Arcari M, Azzali G.
Int J Oncol. 2011 Dec;39(6):1521-7. doi: 10.3892/ijo.2011.1136.
11. Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel.
Hassan MK, Watari H, Christenson L, Bettuzzi S, Sakuragi N.
Tumour Biol. 2011 Oct;32(5):1031-47. doi: 10.1007/s13277-011-0207-0.
12. mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer.
Bhutia SK, Das SK, Kegelman TP, Azab B, Dash R, Su ZZ, Wang XY, Rizzi F, Bettuzzi S, Lee SG, Dent P, Grant S, Curiel DT, Sarkar D, Fisher PB.
J Cell Physiol. 2012 May;227(5):1805-13. doi: 10.1002/jcp.22904. Erratum in: *J Cell Physiol*. 2014 Apr;229(4):531.
13. Molecular mechanisms of the antimetastatic activity of nuclear clusterin in prostate cancer cells.
Moretti RM, Mai S, Montagnani Marelli M, Rizzi F, Bettuzzi S, Limonta P.
Int J Oncol. 2011 Jul;39(1):225-34. doi: 10.3892/ijo.2011.1030.
14. Upregulation of clusterin in prostate and DNA damage in spermatozoa from bisphenol A-treated rats and formation of DNA adducts in cultured human prostatic cells.
De Flora S, Micale RT, La Maestra S, Izzotti A, D'Agostini F, Camoirano A, Davoli SA, Troglio MG, Rizzi F, Davalli P, Bettuzzi S.
Toxicol Sci. 2011 Jul;122(1):45-51. doi: 10.1093/toxsci/kfr096.
15. The clusterin paradigm in prostate and breast carcinogenesis.
Rizzi F, Bettuzzi S.
Endocr Relat Cancer. 2010 Jan 29;17(1):R1-17. doi: 10.1677/ERC-09-0140. 15.
16. Conclusions and perspectives.
Bettuzzi S. *Adv Cancer Res*. 2009;105:133-50. doi: 10.1016/S0065-230X(09)05008-8. Review.
17. Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis.
Sala A, Bettuzzi S, Pucci S, Chayka O, Dews M, Thomas-Tikhonenko A.
Adv Cancer Res. 2009;105:115-32. doi: 10.1016/S0065-230X(09)05007-6. Review.
18. Clusterin (CLU) and lung cancer.
Panico F, Rizzi F, Fabbri LM, Bettuzzi S, Luppi F.
Adv Cancer Res. 2009;105:63-76. doi: 10.1016/S0065-230X(09)05004-0. Review.
19. Clusterin (CLU) and prostate cancer.
Rizzi F, Bettuzzi S.
Adv Cancer Res. 2009;105:1-19. doi: 10.1016/S0065-230X(09)05001-5. Review.
20. Chapter 5: Nuclear CLU (nCLU) and the fate of the cell.
Bettuzzi S, Rizzi F.
Adv Cancer Res. 2009;104:59-88. doi: 10.1016/S0065-230X(09)04005-6. Review.
21. Chapter 3: The shifting balance between CLU forms during tumor progression.
Pucci S, Bettuzzi S.
Adv Cancer Res. 2009;104:25-32. doi: 10.1016/S0065-230X(09)04003-2. Review.
22. Chapter 2: Clusterin (CLU): From one gene and two transcripts to many proteins.
Rizzi F, Coletta M, Bettuzzi S.

- Adv Cancer Res. 2009;104:9-23. doi: 10.1016/S0065-230X(09)04002-0. Review.
23. Chapter 1: Introduction.
Bettuzzi S.
- Adv Cancer Res. 2009;104:1-8. doi: 10.1016/S0065-230X(09)04001-9.
24. Genetic inactivation of ApoJ/clusterin: effects on prostate tumorigenesis and metastatic spread.
Bettuzzi S, Davalli P, Davoli S, Chayka O, Rizzi F, Belloni L, Pellacani D, Fregni G, Astancolle S, Fassan M, Corti A, Baffa R, Sala A.
Oncogene. 2009 Dec 10;28(49):4344-52. doi: 10.1038/onc.2009.286.
25. Epigenetic DNA-(cytosine-5-carbon) modifications: 5-aza-2'-deoxycytidine and DNA-demethylation.
Patra SK, Bettuzzi S.
Biochemistry (Mosc). 2009 Jun;74(6):613-9. Review.
26. Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.
Chayka O, Corvetta D, Dews M, Caccamo AE, Piotrowska I, Santilli G, Gibson S, Sebire NJ, Himoudi N, Hogarty MD, Anderson J, Bettuzzi S, Thomas-Tikhonenko A, Sala A.
J Natl Cancer Inst. 2009 May 6;101(9):663-77. doi: 10.1093/jnci/djp063.
27. Targeting Clusterin in prostate cancer.
Rizzi F, Bettuzzi S.
J Physiol Pharmacol. 2008 Dec;59 Suppl 9:265-74. Review.
28. Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): specificity and interaction with membrane lipid rafts.
Patra SK, Rizzi F, Silva A, Rugina DO, Bettuzzi S.
J Physiol Pharmacol. 2008 Dec;59 Suppl 9:217-35. Review.
29. Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells.
Rizzi F, Caccamo AE, Belloni L, Bettuzzi S.
J Cell Physiol. 2009 May;219(2):314-23. doi: 10.1002/jcp.21671.
30. A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR.
Rizzi F, Belloni L, Crafa P, Lazzaretti M, Remondini D, Ferretti S, Cortellini P, Corti A, Bettuzzi S. PLoS One. 2008;3(10):e3617. doi: 10.1371/journal.pone.0003617.
31. Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer.
McCarthy S, Caporali A, Enkemann S, Scaltriti M, Eschrich S, Davalli P, Corti A, Lee A, Sung J, Yeatman TJ, Bettuzzi S.
Mol Oncol. 2007 Sep;1(2):196-204. doi: 10.1016/j.molonc.2007.05.007.
32. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update.
Brausi M, Rizzi F, Bettuzzi S.
Eur Urol. 2008 Aug;54(2):472-3. doi: 10.1016/j.eururo.2008.03.100.
33. Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development.
Patra SK, Patra A, Rizzi F, Ghosh TC, Bettuzzi S.
Cancer Metastasis Rev. 2008 Jun;27(2):315-34. doi: 10.1007/s10555-008-9118-y. Review.
34. Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis.
Moretti RM, Montagnani Marelli M, Mai S, Cariboni A, Scaltriti M, Bettuzzi S, Limonta P.
Cancer Res. 2007 Nov 1;67(21):10325-33.
35. B-MYB is hypophosphorylated and resistant to degradation in neuroblastoma: implications for cell survival.
Schwab R, Caccamo A, Bettuzzi S, Anderson J, Sala A.
Blood Cells Mol Dis. 2007 Nov-Dec;39(3):263-71.
36. Epigenetic DNA-methylation regulation of genes coding for lipid raft-associated components: a role for raft proteins in cell transformation and cancer progression (review).

- Patra SK, Bettuzzi S.
Oncol Rep. 2007 Jun;17(6):1279-90. Review.
37. Creating prodynorphin-expressing stem cells alerted for a high-throughput of cardiogenic commitment.
Maioli M, Asara Y, Pintus A, Ninniri S, Bettuzzi S, Scaltriti M, Galimi F, Ventura C.
Regen Med. 2007 Mar;2(2):193-202.
38. Establishment of an organotypic in vitro culture system and its relevance to the characterization of human prostate epithelial cancer cells and their stromal interactions.
Papini S, Rosellini A, De Matteis A, Campani D, Selli C, Caporali A, Bettuzzi S, Revoltella RP.
Pathol Res Pract. 2007;203(4):209-16.
39. Clinical relevance of the inhibitory effect of green tea catechins (GtCs) on prostate cancer progression in combination with molecular profiling of catechin-resistant tumors: an integrated view.
Bettuzzi S, Rizzi F, Belloni L.
Pol J Vet Sci. 2007;10(1):57-60. Review.
40. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.
Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A.
Cancer Res. 2006 Jan 15;66(2):1234-40.
41. Nuclear clusterin accumulation during heat shock response: implications for cell survival and thermo-tolerance induction in immortalized and prostate cancer cells.
Caccamo AE, Desenzani S, Belloni L, Borghetti AF, Bettuzzi S.
J Cell Physiol. 2006 Apr;207(1):208-19.
42. Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling.
Scaltriti M, Belloni L, Caporali A, Davalli P, Remondini D, Rizzi F, Astancolle S, Corti A, Bettuzzi S. Carcinogenesis. 2006 May;27(5):1047-53.
43. Spermidine/spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin.
Marverti G, Giuseppina Monti M, Pegg AE, McCloskey DE, Bettuzzi S, Ligabue A, Caporali A, D'Arca D, Moruzzi MS.
Carcinogenesis. 2005 Oct;26(10):1677-86.
44. Ca²⁺ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells.
Caccamo AE, Scaltriti M, Caporali A, D'Arca D, Corti A, Corvetta D, Sala A, Bettuzzi S.
Cell Death Differ. 2005 Jan;12(1):101-4.
45. Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis.
Scaltriti M, Bettuzzi S, Sharrard RM, Caporali A, Caccamo AE, Maitland NJ.
Br J Cancer. 2004 Nov 15;91(10):1842-50.
46. Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent.
Chen T, Turner J, McCarthy S, Scaltriti M, Bettuzzi S, Yeatman TJ.
Cancer Res. 2004 Oct 15;64(20):7412-9.
47. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression.
Caporali A, Davalli P, Astancolle S, D'Arca D, Brausi M, Bettuzzi S, Corti A.
Carcinogenesis. 2004 Nov;25(11):2217-24.
48. Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells¹.
Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S.
Cancer Res. 2004 Sep 1;64(17):6174-82.
49. Cell detachment and apoptosis induction of immortalized human prostate epithelial cells

- are associated with early accumulation of a 45 kDa nuclear isoform of clusterin.
Caccamo AE, Scaltriti M, Caporali A, D'Arca D, Scorcioni F, Astancolle S, Mangiola M, Bettuzzi S. *Biochem J*. 2004 Aug 15;382(Pt 1):157-68.
50. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia.
Crescioli C, Ferruzzi P, Caporali A, Scaltriti M, Bettuzzi S, Mancina R, Gelmini S, Serio M, Villari D, Vannelli GB, Colli E, Adorini L, Maggi M.
Eur J Endocrinol. 2004 Apr;150(4):591-603.
51. Nuclear translocation of a clusterin isoform is associated with induction of anoikis in SV40-immortalized human prostate epithelial cells.
Caccamo AE, Scaltriti M, Caporali A, D'Arca D, Scorcioni F, Candiano G, Mangiola M, Bettuzzi S. *Ann N Y Acad Sci*. 2003 Dec;1010:514-9.
52. Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer.
Scaltriti M, Brausi M, Amorosi A, Caporali A, D'Arca D, Astancolle S, Corti A, Bettuzzi S.
Int J Cancer. 2004 Jan 1;108(1):23-30.
53. Cisplatin-resistance modulates the effect of protein synthesis inhibitors on spermidine/spermine N(1)-acetyltransferase expression.
Marverti G, Monti MG, Bettuzzi S, Caporali A, Astancolle S, Moruzzi MS.
Int J Biochem Cell Biol. 2004 Jan;36(1):123-37.
54. The new anti-oncogene clusterin and the molecular profiling of prostate cancer progression and prognosis.
Bettuzzi S.
Acta Biomed. 2003 Aug;74(2):101-4. English, Italian.
55. Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study.
Bettuzzi S, Scaltriti M, Caporali A, Brausi M, D'Arca D, Astancolle S, Davalli P, Corti A.
Cancer Res. 2003 Jul 1;63(13):3469-72.
56. Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog.
Crescioli C, Ferruzzi P, Caporali A, Mancina R, Comerci A, Muratori M, Scaltriti M, Vannelli GB, Smiroldo S, Mariani R, Villari D, Bettuzzi S, Serio M, Adorini L, Maggi M.
Endocrinology. 2003 Jul;144(7):3046-57.
57. Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis.
Filippi S, Luconi M, Granchi S, Vignozzi L, Bettuzzi S, Tozzi P, Ledda F, Forti G, Maggi M.
Endocrinology. 2002 Nov;143(11):4271-80. Erratum in: *Endocrinology* 2002 Dec;143(12):4543.
58. Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression.
Bettuzzi S, Scorcioni F, Astancolle S, Davalli P, Scaltriti M, Corti A.
Oncogene. 2002 Jun 20;21(27):4328-34.
59. Androgen responsiveness and intrarenal localization of transcripts coding for the enzymes of polyamine metabolism in the mouse.
Bettuzzi S, Strocchi P, Davalli P, Marinelli M, Furci L, Corti A.
Biochem Cell Biol. 2001;79(2):133-40.
60. Manipulation of the expression of regulatory genes of polyamine metabolism results in specific alterations of the cell-cycle progression.
Scorcioni F, Corti A, Davalli P, Astancolle S, Bettuzzi S.
Biochem J. 2001 Feb 15;354(Pt 1):217-23.
61. Differential induction of spermidine/spermine N1-acetyltransferase activity in cisplatin-sensitive and -resistant ovarian cancer cells in response to N1,N12-bis(ethyl)spermine involves transcriptional and post-transcriptional regulation.
Marverti G, Bettuzzi S, Astancolle S, Pinna C, Monti MG, Moruzzi MS.
Eur J Cancer. 2001 Jan;37(2):281-9.

62. Increased levels of clusterin (SGP-2) mRNA and protein accompany rat ventral prostate involution following finasteride treatment.
Astancolle S, Guidetti G, Pinna C, Corti A, Bettuzzi S.
J Endocrinol. 2000 Nov;167(2):197-204.
63. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens.
Bettuzzi S, Davalli P, Astancolle S, Carani C, Madeo B, Tampieri A, Corti A.
Cancer Res. 2000 Jan 1;60(1):28-34. Erratum in: Cancer Res 2000 Mar 1;60(5):1472.
Saverio, B [corrected to Bettuzzi, S]; Pierpaola, D [corrected to Davalli, P]; Serenella, A [corrected to Astancolle, S]; C [corrected to Carani, C]; Bruno, M [corrected to Madeo, B]; Auro, T [corrected to Tampieri, A]; Arnaldo, C [corrected to Corti, A].
64. Clusterin (SGP-2) gene expression is cell cycle dependent in normal human dermal fibroblasts.
Bettuzzi S, Astancolle S, Guidetti G, Moretti M, Tiozzo R, Corti A.
FEBS Lett. 1999 Apr 9;448(2-3):297-300.
65. Coordinate changes of polyamine metabolism regulatory proteins during the cell cycle of normal human dermal fibroblasts.
Bettuzzi S, Davalli P, Astancolle S, Pinna C, Roncaglia R, Boraldi F, Tiozzo R, Sharrard M, Corti A. FEBS Lett. 1999 Mar 5;446(1):18-22.
66. Heparin inhibits phorbol ester-induced ornithine decarboxylase gene expression in endothelial cells.
Pintus G, Tadolini B, Maioli M, Posadino AM, Bennardini F, Bettuzzi S, Ventura C.
FEBS Lett. 1998 Feb 13;423(1):98-104.
67. Different localization of spermidine/spermine N1-acetyltransferase and ornithine decarboxylase transcripts in the rat kidney.
Bettuzzi S, Marinelli M, Strocchi P, Davalli P, Cevolani D, Corti A.
FEBS Lett. 1995 Dec 27;377(3):321-4.
68. Increased levels of clusterin mRNA in the ventral prostate of the aging rat are associated to increases in cuboidal (atrophic) cell population and not to changes in apoptotic activity.
Marinelli M, Quaglino D, Bettuzzi S, Strocchi P, Davalli P, Corti A.
Biochem Cell Biol. 1994 Nov-Dec;72(11-12):515-21.
69. Gene relaxation and aging: changes in the abundance of rat ventral prostate SGP-2 (clusterin) and ornithine decarboxylase mRNAs.
Bettuzzi S, Strocchi P, Marinelli M, Astancolle S, Davalli P, Corti A.
FEBS Lett. 1994 Jul 18;348(3):255-8.
70. Increases in sulphated glycoprotein-2 mRNA levels in the rat brain after transient forebrain ischemia or partial mesodiencephalic hemitransection.
Zoli M, Ferraguti F, Zini I, Bettuzzi S, Agnati LF.
Brain Res Mol Brain Res. 1993 Apr;18(1-2):163-77.
71. Senescence, immortalization, and apoptosis. An intriguing relationship.
Monti D, Grassilli E, Troiano L, Cossarizza A, Salvioli S, Barbieri D, Agnesini C, Bettuzzi S, Ingletti MC, Corti A, et al.
Ann N Y Acad Sci. 1992 Dec 26;673:70-82. Review.
72. SGP-2, apoptosis, and aging.
Grassilli E, Bettuzzi S, Troiano L, Ingletti MC, Monti D, Corti A, Franceschi C.
Ann N Y Acad Sci. 1992 Nov 21;663:471-4.
73. Regional and cellular distribution within the rat prostate of two mRNA species undergoing opposite regulation by androgens.
Bettuzzi S, Zoli M, Ferraguti F, Ingletti MC, Agnati LF, Corti A.
J Endocrinol. 1992 Mar;132(3):361-7.
74. Estrogen and progesterone receptor structure and action in breast cancer cells.
Bettuzzi S, Robinson A, Fuchs-Young R, Greene GL.
Cancer Treat Res. 1992;61:301-15.

75. Studies on the relationship between cell proliferation and cell death: opposite patterns of SGP-2 and ornithine decarboxylase mRNA accumulation in PHA-stimulated human lymphocytes.
Grassilli E, Bettuzzi S, Monti D, Ingletti MC, Franceschi C, Corti A.
Biochem Biophys Res Commun. 1991 Oct 15;180(1):59-63.
76. The gene for SP-40,40, human homolog of rat sulfated glycoprotein 2, rat clusterin, and rat testosterone-repressed prostate message 2, maps to chromosome 8.
Purrello M, Bettuzzi S, Di Pietro C, Mirabile E, Di Blasi M, Rimini R, Grzeschik KH, Ingletti C, Corti A, Sichel G.
Genomics. 1991 May;10(1):151-6.
77. In vivo accumulation of sulfated glycoprotein 2 mRNA in rat thymocytes upon dexamethasone-induced cell death.
Bettuzzi S, Troiano L, Davalli P, Tropea F, Ingletti MC, Grassilli E, Monti D, Corti A, Franceschi C. Biochem Biophys Res Commun. 1991 Mar 29;175(3):810-5.
78. DNA and cell death.
Monti D, Troiano L, Tropea F, Grassilli E, Cossarizza A, Barozzi D, Bettuzzi S, Corti A, Franceschi C. Cytotechnology. 1991 Feb;5(Suppl 1):74-7.
79. Regional increases in ornithine decarboxylase mRNA levels in the rat brain after partial mesodiencephalic hemitranssection as revealed by in situ hybridization histochemistry.
Zoli M, Bettuzzi S, Ferraguti F, Ingletti MC, Zini I, Fuxe K, Agnati LF, Corti A.
Neurochem Int. 1991;18(3):347-52.
81. Identification of an androgen-repressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis.
Bettuzzi S, Hiipakka RA, Gilna P, Liao ST. Biochem J. 1989 Jan 1;257(1):293-6.

Indici bibliometrici riferiti a
Settembre 2016

International full papers, as reviewed by PubMed (ISI): 80
Average Impact Factor: 4.2
Total Impact Factor: > 350
International abstracts: > 200

Author Impact Analysis according to:

- Google Scholar:

citations > 7179 citations; H-index = 33; i10-index = 71

- Harzing's Publish or Perish:

total papers = 163; citations > 6903; H-index = 33; cites/year: 203;
cites/paper: 42

Abstracts internazionali

Oltre 200 abstract accettati in congressi internazionali

Chair

Chair a numerosi congressi internazionali, tra i quali:

EAU

ESUR

AACR

Clusterin/Apolipoprotein J (CLU) Workshop

COST 917

British Prostate Group (BPG)
World Congress on Urological Research

Invited Speaker presso numerose istituzioni di ricerca internazionali,
tra cui:

Imperial College, London
Institute of Food Research, Norwich, UK
Lee Moffitt Cancer Center, Florida, USA
Ben May Institute for Cancer Research, Chicago, USA
YCR Cancer Research Unit, York, UK

Affiliazioni

Dipartimento di Medicina e Chirurgia
Unità di Biochimica, Oncologia Molecolare e Traslazionale
Università degli Studi di Parma
Via Voltorno, 39
43126 PARMA - ITALY

INBB, Istituto Nazionale Biostrutture e Biosistemi,
Viale Medaglie d'Oro, 305
00136 Roma – Italy

COMT, Centro di Oncologia Molecolare e Traslazionale,
Via G.P. Usberti 11/A
43100 Parma - Italy
UNIPR, INBB, COMT

Seminari ad invito

Numerosissimi I seminari ad invito ricevuti presso importanti istituzioni straniere e congressi internazionali. Eccone un elenco parziale, a titolo di esempio:

- 9th World Congress on Advances in Oncology Hersonissos, Crete, Greece
- 7th International Symposium on Molecular Medicine, Hersonissos, Crete, Greece
- 4th Workshop on Clusterin/ApoJ, Villars-sur-Ollon, Switzerland
- 9th International Congress on Amino Acids and Proteins, Vienna
- AACR: Frontiers in Cancer Prevention Research, Baltimore, MD, USA
- EAU Annual Congress, Paris, France
- International Conference on the Role of Polyamines and their Analogs in Cancer and other Diseases, Tivoli, Italy
- Fifth Annual AACR International Conference: Frontiers in Cancer Prevention Research, Boston MA, USA
- Warsaw Division of Polish Society of Veterinary Sciences and the Department of Physiological Sciences, University of Warsaw, Warsaw, Poland
- Polyphenon E: Mechanism of Action Expert Meeting - East Rutherford, New Jersey, USA
- 7th World Basic Urological Research Congress Dublin
- ICPH 3rd International Conference on Polyphenols and Health, Kyoto International Conference Center, Kyoto, Japan
- "Advances in antioxidants (trace elements, vitamins and polyphenols): Molecular mechanisms, nutritional and clinical aspects. 5th International Meeting Monastir – Sousse,

Tunisia

- 5th Clusterin/Apolipoprotein J (CLU) Workshop, Spetses island, Greece
- "Joint Italian-Japanese International Meeting Salerno, Italy
- 24th Congress of the Polish Physiological Society, Lublin, Poland
- Keynote Lecture at the Institute of Food Research, Norwich, UK
- 7th International Symposium "Prospects for the 3rd Millennium Agriculture" Cluj-Napoca, Romania
- BIO Spring 2010 Barcellona, Spain
- 3rd World Congress on Tea & Health: Nutraceutical and Pharmaceutical Applications. Dubai, EAU
- ICOS 2013 Shizuoka, Japan
- 42nd International Symposium of the Princess Takamatsu Cancer Research Fund, Tokio, Japan
- XXVII-th Congress of Polish Physiological Society in Białystok 2017
- 2017 SBUR/ESUR Fall Symposium, Tampa FL., USA

Appartenenza a gruppi / associazioni

- Società Italiana di Biochimica (SIB), 1999.
- Istituto Nazionale Biostrutture e Biosistemi (INBB), membro del Direttivo, 2001.
- Società di Medicina e Scienze Naturali di Parma, 2002.
- European Society of Urological Research (ESUR), 2003; membro del Direttivo dal 2013.
- American Association for Cancer Research (AACR), 2004.
- European Association of Urology (EAU), 2006.
- Centre of Molecular and Translational Oncology (COMT), Vice-Presidente dal 2008.

Responsabilità Editoriali

- Editorial Board Member di:
 1. World Journal of Translational Medicine – WJTM (2012)
 2. Romanian Journal of Oncology and Hematology (2013)
 3. International Journal of Cancer Research and Molecular Mechanisms – IJCRMM (2016)

Editor di Advances in Cancer Research, 2009
(5-years Impact Factor: 5.485)



Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Data: Parma, 3 Luglio 2017